Industrial studies

MOLECULE SPONSOR Acronym PHASE STUDY TITLE LINK
PXT002331 PREXTON AMBLED IIa A Multi-centre, Double-blind, Randomised, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety and Tolerability of 28-Day Oral Treatment with PXT002331 (foliglurax) in Reducing Motor Complications of Levodopa Therapy in Subjects with Parkinson’s Disease Experiencing End-of-dose Wearing Off and Levodopa-Induced Dyskinesia
 
  https://parkinson.network/sites/default/files/logo_ns-park_mini.jpg  
 
Apomorphine / device ORKYN OPTIPARK 2.0 NA Use an Actimetry procedure during initiation of treatment with apomorphine delivered by a pump in patients with Parkinson's disease _
IPT803 TOOLS4PATIENT   POC A Proof of Concept Study to Investigate the Effect of IPT803 Adjunct Treatment in Patients with Parkinson’s Disease.
 
  https://parkinson.network/sites/default/files/logo_ns-park_mini.jpg  
 
THN102-202 THERANEXUS   IIa Randomised, double-blind, placebo-controlled, complete 3-way cross-over phase IIa trial to investigate safety and efficacy of two THN102 doses in subjects with excessive daytime sleepiness associated with Parkinson’s disease
 
  https://parkinson.network/sites/default/files/logo_ns-park_mini.jpg  
 
BIIB054  BIOGEN SPARK IIa A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, with an Active-Treatment Dose-Blinded Period, to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects with Parkinson’s Disease
 
  https://parkinson.network/sites/default/files/logo_ns-park_mini.jpg  
 
APL-130277 SUNOVION   III An Open-Label, Randomized, Crossover Trial utilizing a Single-Blinded Rater to evaluate APL-130277 compared to s.c. Apomorphine in Levodopa Responsive Subjects with Parkinson’s Disease Complicated by Motor Fluctuations
 
  https://parkinson.network/sites/default/files/logo_ns-park_mini.jpg  
 
English